Amoxicillin/clavulanate for infections in infants and children: Past, present and future

Pediatric Infectious Disease Journal

Volumn 22, Issue 8 SUPPL., 2003, Pages

  Klein, Jerome O ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

Amoxicillin; Amoxicillin clavulanate; Clavulanic acid; High dose amoxicillin clavulanate

Indexed keywords

6 AMINOPENICILLANIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AUGMENTIN ES 600; AZITHROMYCIN; BETA LACTAMASE; CEFALEXIN; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DICLOXACILLIN; ERYTHROMYCIN; LEVOFLOXACIN; LORACARBEF; PENICILLIN G; PENICILLIN V; SULFAMETHOXAZOLE; SULTAMICILLIN; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL INFECTION; BACTERIAL STRAIN; CHILD; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SYNTHESIS; ERADICATION THERAPY; HAEMOPHILUS INFLUENZAE; HISTORY OF MEDICINE; HUMAN; INFANT; INFECTION CONTROL; INFECTION PREVENTION; MIDDLE EAR; MORAXELLA CATARRHALIS; MYRINGOTOMY; NAUSEA; OTITIS MEDIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0042737632     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200308001-00005     Document Type: Review

References (43)

1. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
2. Mann CH, consulting ed. Comparative assessment of the broad-spectrum penicillins and other antibiotics. Ann NY Acad Sci 1967;145:207-521.
3. Neu HC, guest ed. International Symposium on Amoxicillin: Clinical Perspectives. J Infect Dis 1974;S121-274.
4. Neu HC. Progress and perspectives on beta-lactamase inhibition: a review of Augmentin. Postgrad Med 1984:1-291.
5. Klein JO, Finland M. The new penicillins. N Engl J Med 1963;269:1019-25.
6. Block S, Hedrick J, Harrison CJ, Chartrand S. MICs of penicillin-resistant S. pneumoniae (PRSP) from acute otitis media [Abstract E24]. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995.
7. Augmentin ES-600® prescribing information. Philadelphia: GlaxoSmithKline, 2002.
8. Neu HC. Antimicrobial activity and human pharmacology of amoxicillin. J Infect Dis 1974;129(Suppl):S123-31.
9. Jackson D, Cooper DL, Filer CW, Langley PF. Augmentin: absorption, excretion and pharmacokinetic studies in man. Postgrad Med Special Rep 1984;Sept/Oct:51-70.
10. Kaye CM, Allen A, Perry S, et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001;23:578-84.
11. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
12. Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1997;16:710-1.
13. Steele RW, Thomas MP, Begue RE, Despinasse BP. Selection of pediatric antibiotic suspensions: taste and cost factors. Infect Med 1999;16:197-200.
14. Demers DM, Chan DS, Bass JW. Antimicrobial drug suspensions: a blinded comparison of taste of twelve common pediatric drugs including cefixime, cefpodoxime, cefprozil and loracarbef. Pediatr Infect Dis J 1994;13:87-9.
15. Matsui D, Lim R, Tschen T, Rieder MJ. Assessment of the palatability of beta-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997;151:599-602.
16. Thornsberry C, Ogilvie PT, Holley HP Jr, Sahm DF. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective US study. Antimicrob Agents Chemother 1999;43:2612-23.
17. Jacobs MR, Bajaksouzian S, Zilles A, et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrob Agents Chemother 1999;43:1901-8.
18. Jacobs MR, Dagan R, Appelbaum PC, Burch DJ. Prevalence of antimicrobial-resistant pathogens in middle ear fluid: multinational study of 917 children with acute otitis media. Antimicrob Agents Chemother 1998;42:589-95.
19. Tomeh MO, Starr SE, McGowan JE Jr, Terry PM, Nahmias AJ. Ampicillin-resistant Haemophilus influenzae type B infection. JAMA 1974;229:295-7.
20. Khan W, Ross S, Rodriguez W, Controni G, Saz AK. Haemophilus influenzae type B resistant to ampicillin: a report of two cases. JAMA 1974;229:298-301.
21. Doern GV, Brueggemann AB, Pierce G, Holley HP Jr, Rauch A. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study. Antimicrob Agents Chemother 1997;41:292-7.
22. Barry AL, Fuchs PC, Pfaller MA. Susceptibilities of beta-lactamase-producing and -nonproducing ampicillin-resistant strains of Haemophilus influenzae to ceftibuten, cefaclor, cefuroxime, cefixime, cefotaxime, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1993;37:14-8.
23. Ubukata K, Shibasaki Y, Yamamoto K, et al. Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 2001;45:1693-9.
24. Malmvall BE, Brorsson JE, Johnsson J. In vitro sensitivity to penicillin V and beta-lactamase production of Branhamella catarrhalis. J Antimicrob Chemother 1977;3:374-5.
25. Nissinen A, Gronroos P, Huovinen P, et al. Development of beta-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. Clin Infect Dis 1995;21:1193-6.
26. Doern GV, Brueggemann AB, Pierce G, Hogan T, Holley HP Jr, Rauch A. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996;40:2884-6.
27. Centers for Disease Control and Prevention. Multidrug-resistant Streptococcus pneumoniae in a child care center: southwest Georgia, December 2000. MMWR 2002;50:1156-8.
28. Ghaffar F, Muniz LS, Katz K, et al. Effects of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal alpha-hemolytic streptococci, and Staphylococcus aureus in children with acute otitis media. Clin Infect Dis 2002;34:1301-9.
29. Varon E, Levy C, De La Rocque F, et al. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections. Clin Infect Dis 2000;31:477-81.
30. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973-5.
31. Dagan R. Treatment of acute otitis media: challenges in the era of antibiotic resistance. Vaccine 2001;19:S9-16.
32. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001;20:829-37.
33. Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: meta-analysis of 5400 children from thirty-three randomized trials. J Pediatr 1994;124:355-67.
34. Dagan R, McCracken GH. Flaws in design and conduct of clinical trials in acute otitis media. Pediatr Infect Dis J 2002;21:894-902.
35. Dowell SF. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics 1998;101:163-84.
36. Dowell SF, Marcy SM, Phillips W, Gerber MA, Schwartz B. Otitis media: principles of judicious use of antimicrobial agents. Pediatrics 1998;101:165-71.
37. Klein JO. Review of consensus reports on management of acute otitis media. Pediatr Infect Dis J 1999;18:1152-5.
38. Wald ER. Acute otitis media: more trouble with the evidence. Pediatr Infect Dis J 2003;22:103-4.
39. Aspin MM, Hoberman A, McCarty J, et al. Comparative study of the safety and efficacy of clarithromycin and amoxicillin-clavulanate in the treatment of acute otitis media in children. J Pediatr 1994;125:136-41.
40. McLinn SE, Moskal M, Goldfarb J, et al. Comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions in treatment of acute otitis media with effusion in children. Antimicrob Agents Chemother 1994;38:315-8.
41. Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and reduced occurrence of diarrhea from a new formulation of amoxicillin/clavulanate potassium (Augmentin) for treatment of acute otitis media in children. Pediatr Infect Dis J 1997;16:463-70.
42. Mitchell DK, Van R, Mason EH, Norris DM, Pickering LK. Prospective study of toxigenic Clostridium difficile in children given amoxicillin/clavulanate for otitis media. Pediatr Infect Dis J 1996;15:514-9.
43. Harrison CJ. Amoxicillin-clavulanate (Augmentin): an update. Rep Pediatr Infect Dis 1992;2:26-7.